How Can Targeting Signaling Networks Help in Cancer Therapy?
Targeting dysregulated signaling pathways offers a promising approach for cancer therapy. Small molecule inhibitors, monoclonal antibodies, and other therapeutic agents can specifically inhibit components of these pathways. For example:
- Tyrosine kinase inhibitors (TKIs) can block the activity of overactive kinases in the PI3K/AKT/mTOR and RAS/RAF/MEK/ERK pathways. - Monoclonal antibodies can target and neutralize specific receptors or ligands involved in cancer signaling. - mTOR inhibitors can reduce cell growth and proliferation by inhibiting the mTOR kinase.
